Connection
David Raben to Angiogenesis Inhibitors
This is a "connection" page, showing publications David Raben has written about Angiogenesis Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.696 |
|
|
|
-
Frederick B, Gustafson D, Bianco C, Ciardiello F, Dimery I, Raben D. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Jan 01; 64(1):33-7.
Score: 0.224
-
Raben D, Ryan A. Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005? Clin Lung Cancer. 2005 Nov; 7(3):175-9.
Score: 0.221
-
Raben D, Helfrich B. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer? Clin Lung Cancer. 2004 Jul; 6(1):48-57.
Score: 0.202
-
Raben D, Helfrich B, Bunn PA. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys. 2004; 59(2 Suppl):27-38.
Score: 0.049